Nuclear Medicine

Nuclear medicine (also called molecular imaging) includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. Nuclear imaging is achieved by injecting small amounts of radioactive material (radiopharmaceuticals) into patients before or during their scan. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT. But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders.

Lantheus completes sale of SPECT business
Lantheus has signaled that the decision to sell its SPECT business will allow the company to focus more on growing its portfolio of PET radiodiagnostics and microbubbles.
Positron raises $2M to expand PET-CT commercialization
The New York-based imaging company is now focused on expanding sales for the cost-effective PET-CT system it developed with Neusoft Medical Systems.
Stanford Medicine’s Department of Radiology inks partnership with Novartis
They’ll work to accelerate research and development around targets for radioligand imaging across a wide range of oncological applications.
Leading nuclear medicine organizations collaborate to streamline PET accreditation
The groups have jointly endorsed a unified framework “to standardize and harmonize quantitative PET imaging worldwide.”
Class action lawsuit claims imaging agent developer Telix Pharmaceuticals misled investors
Alleged transgressions took place between February and August, including the FDA rejecting Telix’s application for a new brain cancer imaging agent.

Lantheus completes sale of SPECT business

Lantheus has signaled that the decision to sell its SPECT business will allow the company to focus more on growing its portfolio of PET radiodiagnostics and microbubbles.

Positron NeuSight PET-CT 64 slice scanner

Positron raises $2M to expand PET-CT commercialization

The New York-based imaging company is now focused on expanding sales for the cost-effective PET-CT system it developed with Neusoft Medical Systems.

Stanford Medicine’s Department of Radiology inks partnership with Novartis

They’ll work to accelerate research and development around targets for radioligand imaging across a wide range of oncological applications.

Leading nuclear medicine organizations collaborate to streamline PET accreditation

The groups have jointly endorsed a unified framework “to standardize and harmonize quantitative PET imaging worldwide.”

statue justice legal verdict malpractice case lawsuit scale

Class action lawsuit claims imaging agent developer Telix Pharmaceuticals misled investors

Alleged transgressions took place between February and August, including the FDA rejecting Telix’s application for a new brain cancer imaging agent.

Copper-based radiotracer excels at PSMA imaging

Copper-based PSMA radiotracer shines in clinical trial

The tracer's extended half-life of over three hours could make it a promising candidate for future prostate cancer diagnostics.

Imaging advocates express frustration with final hospital outpatient payment rule

Medicare is reassigning one CPT code for SPECT scans, which will result in a 57% reduction in reimbursement for certain imaging exams.

Telix says new kidney cancer imaging agent alters treatment plans for 50% of patients

The positive findings come after the U.S. Food and Drug Administration previously shared concerns related to sterility assurance issues during the drug’s production.